Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis (INT-210-II102)

2 luglio 2026 aggiornato da: Innatus Therapeutics (Shanghai) Co., Ltd.

A Multicenter, Randomized, Open-label Clinical Study to Evaluate the Safety and Efficacy of INT-210 Capsules in Participants With Active Ulcerative Colitis

A Multicenter, Randomized, Open-label Clinical Study to Evaluate the Safety and Efficacy of INT-210 Capsules in Participants with Active Ulcerative Colitis.

The study aims to evaluate the safety, efficacy, pharmacokinetic (PK) characteristics, pharmacodynamic (PD) characteristics of INT-210 in participants with active ulcerative colitis (UC).

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

24

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

  • Cina
      • Beijing, Cina
        • Reclutamento
        • Beijing Chao-yang Hospital, Capital Medical University
        • Contatto:
      • Beijing, Cina
        • Reclutamento
        • Beijing Friendship Hospital, Capital Medical University
        • Contatto:
      • Beijing, Cina
        • Reclutamento
        • Beijing Luhe Hospital, Capital Medical University
        • Contatto:
      • Guangzhou, Cina
        • Reclutamento
        • The First Affiliated Hospital, Sun Yat-Sen University
        • Contatto:
      • Guangzhou, Cina
        • Reclutamento
        • Guangzhou First People's Hospital
        • Contatto:
      • Hangzhou, Cina
        • Reclutamento
        • The First Affiliated Hospital, Zhejiang University School of Medicine
        • Contatto:
      • Shanghai, Cina
        • Reclutamento
        • XinHua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
        • Contatto:
      • Taiyuan, Cina
        • Reclutamento
        • Shanxi Bethune Hospital
        • Contatto:
      • Weifang, Cina
      • Wenzhou, Cina
        • Reclutamento
        • The Second Affiliated Hospital of Wenzhou Medical University
        • Contatto:
      • Wuhan, Cina
        • Reclutamento
        • Renmin Hospital of Wuhan University
        • Contatto:
      • Xi'an, Cina
        • Reclutamento
        • Xijing Hospital (The First Affiliated Hospital of Air Force Medical University)
        • Contatto:
      • Xinxiang, Cina
        • Reclutamento
        • The First Affiliated Hospital of Henan Medical University
        • Contatto:
    • Guangdong
      • Guangzhou, Guangdong, Cina
        • Reclutamento
        • The Sixth Affiliated Hospital, Sun Yat-sen University
        • Contatto:
    • Liaoning
      • Shenyang, Liaoning, Cina
        • Reclutamento
        • Shengjing Hospital of China Medical University
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  1. Voluntarily participate in the study and sign the informed consent form (ICF);
  2. Males or females aged ≥18 and ≤75 years at the time of signing the ICF;
  3. Diagnosed with UC for ≥3 months at the time of signing the ICF, with the diagnosis of UC supported by clinical manifestations and colonoscopy evidence, and confirmed by a histopathology report (pre-randomization colonoscopy and histopathology examination are acceptable as supporting evidence);
  4. Active UC, defined as: a modified Mayo score (including hematochezia, stool frequency, and endoscopy findings) of 4-9, with an endoscopy subscore of ≥2 (confirmed by central reading) and a hematochezia subscore of ≥1 in the Mayo score;
  5. At pre-randomization colonoscopy, the extent of UC lesions extends beyond the rectum (active disease ≥15 cm from the anal verge on colonoscopy, confirmed by central reading);
  6. Participants must have had an inadequate response or intolerance to at least one of the following UC treatments (inadequate response is defined as that the participant has previously discontinued the corresponding drug due to lack of efficacy as judged by the investigator; intolerance is defined as that the participant has previously discontinued the drug due to adverse reactions as judged by the investigator): oral sulfasalazine (SASP) and/or 5- aminosalicylate (5-ASA); oral corticosteroids; azathioprine or 6- mercaptopurine; marketed anti-tumor necrosis factor-α (TNF-α) agents: infliximab or adalimumab, etc.; vedolizumab; marketed JAK inhibitors: tofacitinib, upadacitinib, etc.; marketed interleukin 12/23 (IL-12/23) inhibitors: ustekinumab, etc.; selective sphingosine-1-phosphate (S1P) receptor modulators: etrasimod, etc.; sulfasalazine (SASP) and/or 5- aminosalicylate (5-ASA); oral corticosteroids; azathioprine or 6- mercaptopurine; marketed anti-tumor necrosis factor-α (TNF-α) agents: infliximab or adalimumab, etc.; vedolizumab; marketed JAK inhibitors: tofacitinib, upadacitinib, etc.; marketed interleukin 12/23 (IL-12/23) inhibitors: ustekinumab, etc.; selective sphingosine-1-phosphate (S1P) receptor modulators: etrasimod, etc.;

  7. If participants are currently using the following drugs to treat UC, they must also meet the following requirements:

    • Glucocorticoid therapy: oral prednisone ≤20 mg/d (or equivalent drug dose) or budesonide ≤9 mg/d or beclomethasone ≤5 mg/d, with a stable dose for at least 2 weeks before the screening colonoscopy;
    • Aminosalicylate preparations: oral sulfasalazine and/or 5- aminosalicylate must be stable for at least ≥2 weeks before the screening colonoscopy and must remain stable during the study;
  8. Throughout the entire study period from the signing of the ICF and for 3 months after the last dose, female participants of childbearing potential and male participants who have not undergone vasectomy must comply with the specified contraception requirements.

Exclusion Criteria:

  1. Pregnant or lactating women, or those planning to become pregnant during the study;
  2. Known allergy to any component of INT-210;
  3. Based on medical history and endoscopy and/or histological results, participants with suspected or confirmed Crohn's disease, unclassified colitis, acute fulminant colitis, toxic megacolon, intestinal perforation, microscopic colitis, ischemic colitis, or radiation colitis;
  4. Participants who have undergone surgery for UC or are planning surgery (including stoma creation, or total or partial proctectomy/colectomy, etc.);

  5. Evidence of unresected adenoma or dysplasia in the colon, including lowgrade or high-grade atypical hyperplasia, and unclassified atypical hyperplasia; presence of high-risk progressive adenoma, defined as:

    ① Adenoma diameter ≥10 mm; or ② Villous adenoma or mixed adenoma with villous structure exceeding 25%; or ③ Accompanied by high-grade intraepithelial neoplasia.

  6. With primary sclerosing cholangitis;
  7. History of alcohol or drug abuse or addiction within one year prior to screening;
  8. Have undergone other major surgery within 6 months prior to screening, or are planning surgery during the study; have a history of myocardial infarction, acute stroke or transient ischemic attack, thrombotic events such as deep vein thrombosis or pulmonary embolism, clinically significant arrhythmia or unstable angina pectoris, coronary artery bypass grafting, or severe or pulmonale or pulmonary arterial hypertension that would affect the evaluation of study results, within 6 months prior to screening;
  9. Presence of clinically severe diseases, such as a history of cardiovascular, hepatic, endocrine, gastrointestinal, metabolic, neurological, pulmonary, or psychiatric diseases, or clinically significant diseases, conditions, or other evidence that the investigator considers would pose a risk to participant safety or interfere with the conduct, progress, or completion of the study;
  10. Have received two or more classes of biological products/small molecule targeted drugs (e.g., anti-TNF-α monoclonal antibodies, anti-integrin antibodies, anti-IL12/23 monoclonal antibodies, JAK inhibitors, S1P receptor modulators) and have been assessed by the investigator as treatment failure (UC disease progression requiring salvage therapy, inability to taper glucocorticoid during the maintenance phase, or need for other effective therapies);

  11. Participants receiving the following drug therapies:

    • Use of non-steroidal anti-inflammatory drugs (excluding stable use of

      ≤100 mg/day aspirin for prevention of cardiovascular and cerebrovascular diseases and temporary use of ≤2000 mg/day acetaminophen for no more than three days for infectious pyrexia or mild to moderate pain), intestinal probiotics (including fecal transplant), fish oil, JAK inhibitors, immunoadsorption therapy, Chinese herbal medicines, or compound preparations containing Chinese herbal medicines within 2 weeks prior to randomization;

    • Use of azathioprine or 6-mercaptopurine, cyclosporine, thalidomide, methotrexate, mycophenolate, tacrolimus/sirolimus within 4 weeks prior to randomization;
    • Use of intravenous corticosteroids within 4 weeks prior to randomization, or rectal corticosteroids or rectal 5-ASA within 2 weeks prior to randomization;
    • Use of interferon or TNF-α inhibitors within 8 weeks prior to randomization;
    • Intravenous immunoglobulin injection or therapeutic plasma exchange within 8 weeks prior to randomization;
    • Use of S1P receptor modulators within 10 weeks prior to randomization;
    • Use of vedolizumab, IL-12/23 antibodies, cyclophosphamide, or chlorambucil within 12 weeks prior to randomization;
    • Use of leflunomide within 12 weeks prior to randomization, unless discontinued for 4 weeks before randomization and accelerated elimination (e.g., oral cholestyramine or activated charcoal) was completed at least 2 weeks prior to randomization, with corresponding medical history records required;
    • Use of rituximab within 1 year prior to randomization;
    • Use of any other investigational or marketed products with immunosuppressive effects within 8 weeks or 5 drug half-lives (whichever is longer) prior to randomization;
  12. Positive for Mycobacterium tuberculosis or judged by the investigator to have a potential M. tuberculosis infection, such as: positive T-SPOT.TB test or purified protein derivative (PPD) induration ≥5 mm (within 3 months prior to screening); chest imaging within 3 months prior to screening suggesting active tuberculosis infection lesions;
  13. History of recurrent invasive fungal infections or other chronic infections; herpes zoster or cytomegalovirus infection within 8 weeks prior to signing the ICF; clinically diagnosed clostridioides difficile infection or other intestinal infections within 30 days before the screening colonoscopy; positive clostridium test result during the screening period; infection requiring systemic anti-pathogen drugs (including antibacterial, antiviral, antifungal, anti-parasitic, etc.) for control within 7 days prior to randomization;
  14. Presence of any disease that may require treatment with systemic glucocorticoid during the study (e.g., moderate to severe asthma, dermatitis atopic, rheumatoid arthritis, etc.);
  15. Malignant tumors within 5 years prior to screening (except for adequately treated or resected basal cell or squamous cell skin cancer); or previous neoplasm screening that did not rule out tumor lesions;
  16. Participants with conditions that may affect the absorption of oral drugs, such as gastrectomy or clinically significant diabetes mellitus-related gastrointestinal diseases, or specific types of obesity surgery such as gastric bypass; participants who have only undergone simple gastric banding-like procedures that divide the stomach into separate pouches are not excluded;
  17. Participants who have undergone small intestine or colon operation and have evidence of colonic dysplasia or intestinal stenosis;

  18. Any of the following abnormalities in screening laboratory tests:

    • Hemoglobin <9 g/dL or white blood cells <3.0×109/L or neutrophils <1.5×109/L, platelets <100×109/L
    • Total bilirubin (TBIL), aspartate transaminase (AST), or alanine transaminase (ALT) ≥1.5 times the upper limit of normal (ULN)
    • Blood creatinine >1.5 times ULN
    • Any other abnormal laboratory test results that the investigator considers may expose the participant to unacceptable risks by participating in this study
    • Positive for hepatitis B surface antigen (HBsAg), or test results are HBsAg negative, hepatitis B core antibody (HBcAb) positive, and positive for hepatitis B virus deoxyribonucleic acid (HBV-DNA); positive for hepatitis C virus antibody (HCV-Ab) and positive for hepatitis C virus ribonucleic acid (HCV-RNA); positive for human immunodeficiency virus (HIV) antibody
    • Positive for intestinal pathogens (excluding colonizing microorganisms interpreted by the investigator to be non-pathogenic);
  19. Clinically significant electrocardiogram abnormal during the screening period, which the investigator judges may increase the participant's safety risk;
  20. Have received any live vaccine within 3 months prior to randomization or plan to receive any live vaccine during the clinical study;
  21. Participants whom the investigator considers have other factors that make them unsuitable for participation in this study.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: 200 mg INT-210 capsule
Droga: INT-210 Capsule
All participants will receive oral treatment with INT-210 capsule 200 mg twice daily, starting from Day 1 (D1) of the treatment period (12 weeks).
Droga: INT-210 Capsule
All participants will receive oral treatment with INT-210 capsule 400 mg twice daily, starting from Day 1 (D1) of the treatment period (12 weeks)
Sperimentale: 400 mg INT-210 capsule
Droga: INT-210 Capsule
All participants will receive oral treatment with INT-210 capsule 200 mg twice daily, starting from Day 1 (D1) of the treatment period (12 weeks).
Droga: INT-210 Capsule
All participants will receive oral treatment with INT-210 capsule 400 mg twice daily, starting from Day 1 (D1) of the treatment period (12 weeks)

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
The incidence of treatment-emergent adverse events
Lasso di tempo: From enrollment through the safety follow-up visit on Day 92
Number of participants with treatment-related adverse events as assessed. The incidence of treatment-emergent adverse events will be measured using a combination of data collection methods, including tracking adverse events and assessing their onset or worsening relative to the initiation of treatment. The most recent version of the Medical Dictionary for Regulatory Activities (MedDRA) preferred terms will be used to classify adverse events, including their relationship to the treatment and maximum severity.
From enrollment through the safety follow-up visit on Day 92
Treatment-emergent potentially clinically- significant abnormalities in safety laboratory parameters-hematology
Lasso di tempo: From enrollment through the safety follow-up visit on Day 92
From enrollment through the safety follow-up visit on Day 92
Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: blood chemistry
Lasso di tempo: From enrollment through the safety follow-up visit on Day 92
From enrollment through the safety follow-up visit on Day 92
Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: serum ferritin
Lasso di tempo: From enrollment through the safety follow-up visit on Day 92
From enrollment through the safety follow-up visit on Day 92
Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: coagulation
Lasso di tempo: From enrollment through the safety follow-up visit on Day 92
From enrollment through the safety follow-up visit on Day 92
Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: urinalysis
Lasso di tempo: From enrollment through the safety follow-up visit on Day 92
From enrollment through the safety follow-up visit on Day 92
Treatment-emergent potentially clinically significant abnormalities in electrocardiogram values: QTcF (milliseconds)
Lasso di tempo: From enrollment through the safety follow-up visit on 92
A standard 12-lead ECG will be used to collect ventricular rate, PR interval, QRS duration, QT interval, QTcF interval (Fridericia's correction), and ECG result description; the participant must rest for at least 5 minutes before the test. The investigator (or designated personnel) will clinically evaluate each 12-lead ECG.
From enrollment through the safety follow-up visit on 92
Treatment-emergent potentially clinically significant abnormalities in vital signs: heart rate (beats per minute)
Lasso di tempo: From enrollment through the safety follow-up visit on Day 92
From enrollment through the safety follow-up visit on Day 92
Treatment-emergent potentially clinically significant abnormalities in vital signs: blood pressure (mmHg)
Lasso di tempo: From enrollment through the safety follow-up visit on Day 92
From enrollment through the safety follow-up visit on Day 92
Treatment-emergent potentially clinically significant abnormalities in vital signs: respiration rate (BPM)
Lasso di tempo: From enrollment through the safety follow-up visit on Day 92
From enrollment through the safety follow-up visit on Day 92
Treatment-emergent potentially clinically significant abnormalities in vital signs: temperature (℃)
Lasso di tempo: From enrollment through the safety follow-up visit on Day 92
From enrollment through the safety follow-up visit on Day 92

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Pharmacokinetics parameter: Cmax of INT-210
Lasso di tempo: From Day 1 to Day 85
Maximum observed plasma concentration
From Day 1 to Day 85
Pharmacokinetics parameter: Cmax_ss of INT-210
Lasso di tempo: rom Day 1 to Day 85
Peak Steady-state Concentration
rom Day 1 to Day 85
Pharmacokinetics parameter: Cmin_ss of INT-210
Lasso di tempo: From Day 1 to Day 85
Trough Steady-state Concentration
From Day 1 to Day 85
Pharmacokinetics parameter: Cave_ss of INT-210
Lasso di tempo: From Day 1 to Day 85
Average Steady-state Blood Drug Level
From Day 1 to Day 85
Pharmacokinetics parameter: AUC0-inf of INT-210
Lasso di tempo: From Day1 to Day 85
Area under the curve from time 0 extrapolated to infinite time (AUCinf) of INT-210
From Day1 to Day 85
Pharmacokinetics parameter: AUC0-t of INT-210
Lasso di tempo: From Day 1 to Day 85
Area Under the Plasma Drug concentration-time Curve from Time 0 to the Last Measurement
From Day 1 to Day 85
Pharmacokinetics parameter: AUCss
Lasso di tempo: From Day 1 to Day 85
Area Under the Steady-state Blood drug Concentration-time Curve
From Day 1 to Day 85
Pharmacokinetics parameter: Tmax of INT-210
Lasso di tempo: From Day 1 to Day 85
Time of maximum observed concentration (Tmax)
From Day 1 to Day 85
Pharmacokinetics parameter: T1/2 of INT-210
Lasso di tempo: From Day 1 to Day 85
Half-life (T1/2) (hours)
From Day 1 to Day 85
Pharmacokinetics parameter: CL/F of INT-210
Lasso di tempo: From Day 1 to Day 85
Apparent Plasma Clearance
From Day 1 to Day 85
Pharmacokinetics parameter: Kel of INT-210
Lasso di tempo: From Day 1 to Day 85
Elimination Rate Constant
From Day 1 to Day 85
Pharmacokinetics parameter: MRT of INT-210
Lasso di tempo: From Day1 to Day 85
Mean Residence Time
From Day1 to Day 85
Pharmacokinetics parameter: Vz/F of INT-210
Lasso di tempo: From Day 1 to Day 85
Apparent Volume of Distribution
From Day 1 to Day 85
Pharmacokinetics parameter: DF of INT-210
Lasso di tempo: From Day 1 to Day 85
Degree of Fluctuation
From Day 1 to Day 85
Pharmacokinetics parameter: RAAUC0-t of INT-210
Lasso di tempo: From Day 1 to Day 85
Accumulation Ratio Calculated Based on AUC
From Day 1 to Day 85
Pharmacokinetics parameter: RACmax of INT-210
Lasso di tempo: From Day 1 to Day 85
Accumulation Ratio Calculated Based on Cmax
From Day 1 to Day 85
Clinical Remission Rate
Lasso di tempo: From Day 0 to Day 85
The modified Mayo score (MMS) is uesd for assessing the disease activity of UC, including the Rectal Bleeding Subscore (RBS), Stool Frequency Subscore (SFS), and Endoscopy Subscore (ES). The score for each sub-item ranges from 0-3, and the total MMS score ranges from 0-9. A higher score indicates more severe disease, and the total score is a comprehensive assessment of active UC. The percentage of participants who, after taking INT-210, achieve a modified Mayo score ≤2, with an ES ≤1 (excluding "friability" assessment), RBS=0, SFS≤1, and with no increase from baseline in the above 3 subscores.
From Day 0 to Day 85
Clinical Response Rate
Lasso di tempo: From Day 0 to Day 85
The percentage of participants who, after taking INT-210, have a decrease in their modified Mayo score of ≥2 points and ≥30% from baseline, and a decrease in RBS of ≥1 point or an absolute RBS of ≤1
From Day 0 to Day 85
Endoscopic Remission Rate
Lasso di tempo: From Day 0 to Day 85
The percentage of participants who, after taking INT-210, have an ES ≤1 (excluding "friability" assessment)
From Day 0 to Day 85
Histological Improvement Rate
Lasso di tempo: From Day 0 to Day 85
The percentage of participants who, after taking INT-210, achieve a Geboes Index Score (GS) ≤3.1, and an ES=0/1 in the MMS (excluding "friability" assessment).
From Day 0 to Day 85
Mucosal Healing Rate
Lasso di tempo: From Day 0 to Day 85
The percentage of participants who, after taking INT-210, have a GS ≤2B.1
From Day 0 to Day 85
Symptomatic Remission Rate
Lasso di tempo: From Day 0 to Day 85
The percentage of participants who, after taking INT-210, have an SFS = 0/1 and an RBS = 0.
From Day 0 to Day 85

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Innatus Therapeutics (Shanghai) Co., Ltd.

Investigatori

  • Investigatore principale: Minhu Chen, First Affiliated Hospital, Sun Yat-Sen University

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

11 giugno 2026

Completamento primario (Stimato)

1 giugno 2028

Completamento dello studio (Stimato)

1 giugno 2028

Date di iscrizione allo studio

Primo inviato

23 giugno 2026

Primo inviato che soddisfa i criteri di controllo qualità

2 luglio 2026

Primo Inserito (Effettivo)

9 luglio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

9 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

2 luglio 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • INT-210-II102
  • CTR20260703 (Altro identificatore: National Medical Products Administration (NMPA))

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Colite ulcerosa (UC)

Prove cliniche su INT-210 Capsule

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Togo

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

3
Sottoscrivi